NCT00708773View on ClinicalTrials.gov

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Advanced Cancer
Interventions
DRUG

Irinotecan

"90 minute IV infusion once every 3 weeks.~Dose will be based on sex and genotype determination."

Trial Locations (2)

60201

NorthShore University HealthSystem, Evanston

60637

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00708773 - Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter